The research, led by corresponding author Lei Zhang, Ph.D., a pharmaceutical engineering professor at Jining Medical University in China, addresses a problem that has long frustrated researchers who mine environmental DNA for drug leads. Microorganisms produce many of the natural products that have become important medicines, and the blueprints for making these compounds are written into their genomes as biosynthetic gene clusters, or BGCs — groups of neighboring genes that work together to produce a specific compound. In theory, sequencing the DNA of soil, ocean, or gut microbes should reveal an enormous trove of these clusters. In practice, the process rarely works that cleanly.

When researchers recover DNA directly from environmental samples — an approach known as metagenomics — the genetic material is typically shredded into short reads that must be assembled into longer contiguous sequences, or contigs. Because microbial genomes are complex and sequencing coverage is uneven, BGCs recovered from these metagenomic assemblies are often fragmented across multiple contigs. As Zhang explained, this fragmentation makes it difficult to reconstruct complete biosynthetic pathways and to determine which clusters are most likely to produce medically useful compounds. A gene cluster split across several disconnected fragments can look like genetic noise, and many potentially valuable pathways are discarded or overlooked as a result.

The strategy developed by Zhang and colleagues begins with a deceptively simple idea: use what is already known to find what is not. The researchers started with biosynthetic gene clusters whose products had already been experimentally characterized and used them as reference maps. They then searched large metagenomic datasets for related pieces of biosynthetic information. When those pieces turned out to be fragmented, the known clusters served as guides to help reconstruct the missing pathway and predict what kinds of molecules it might produce. In effect, the experimentally verified BGCs acted as templates that allowed the team to stitch scattered genetic fragments back into coherent biosynthetic narratives.

This guided reconstruction step is what distinguishes the approach from conventional genome mining, in which each fragment is typically analyzed in isolation. The researchers found that fragmented metagenomic data can contain valuable biosynthetic information that would be missed if every fragment were evaluated separately. By using known biosynthetic gene clusters as guides, they were able to piece together candidate pathways and identify potential bioactive products that no single contig could have revealed on its own. The method effectively converts partial, seemingly unusable genetic data into structured hypotheses about the chemistry of uncultured microbes.

Crucially, the team did not stop at computational prediction. To connect their in silico findings to measurable biology, they chemically synthesized selected predicted compounds and tested their biological activity in the laboratory. According to Zhang, this linkage of computational mining with experimental validation is a central feature of the work. The workflow identifies candidates for reconstruction, product prediction, chemical synthesis, and biological testing, creating a pipeline that moves a hypothesis from fragmented DNA sequence all the way to a molecule that can be pipetted onto living cells.

The experimental results provided an early proof of concept. The researchers chemically synthesized six candidate compounds and tested them across seven cancer cell lines. The compounds showed different patterns of cytotoxic activity, with compounds designated D and E displaying the most notable activity and clear differences emerging among the cancer cell lines. That variation matters: differential activity across cell lines suggests that the molecules interact with biological targets in specific ways rather than acting as indiscriminate toxins, which is a desirable starting point for any potential anticancer agent. The findings also demonstrate that compounds predicted from reconstructed metagenomic pathways can, once synthesized, exhibit genuine bioactivity.

The broader significance of the study lies in what it offers to the natural-products research community. Instead of treating partial BGCs as dead ends, the approach uses experimentally characterized clusters as guides for reconstruction and then focuses experimental resources on candidates that have a stronger basis for further study. In a field where the cost of synthesizing and testing every predicted compound would be prohibitive, this prioritization step is essential. It provides a route for turning incomplete or fragmented biosynthetic gene clusters into testable natural-product hypotheses, concentrating laboratory effort where the computational evidence is strongest.

At the same time, the researchers are careful to frame the limits of their method. Computational reconstruction and product prediction are prioritization steps, not endpoints. Chemical structures, biological activities, and therapeutic value must still be established through appropriate experiments, and further work is needed to confirm the biological mechanisms, activity profiles, and therapeutic potential of the six compounds evaluated. Zhang also noted that it remains to be shown whether the predicted products are actually produced naturally by the corresponding microorganisms — a question that matters both for understanding microbial ecology and for assessing whether these molecules could be sourced biologically rather than synthetically.

Even with those caveats, the study points toward a future in which the unculturable microbial majority becomes an accessible source of medicine rather than a permanent blind spot. As Zhang put it, fragmented metagenomic data should not simply be treated as incomplete or unusable; by using known biosynthetic pathways as guides, researchers can recover hidden biosynthetic information, prioritize promising natural-product candidates, and move them from computational prediction toward experimental testing. With antibiotic resistance rising and the pipeline for new anticancer agents in constant need of replenishment, practical methods for exploring the enormous chemical potential of environmental microbes could not arrive at a better time. The work suggests that the next generation of drugs may be hiding not in exotic organisms, but in the fragmented genetic data that laboratories around the world are already generating every day.

Subject of Research: Reconstruction of fragmented metagenomic biosynthetic gene clusters to discover natural-product drug candidates

Article Title: Mining fragmented data for antibiotics and cancer treatments

Article References: Mining fragmented data for antibiotics and cancer treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: metagenomics, biosynthetic gene clusters, natural products, antibiotics, anticancer compounds, drug discovery, microbiology, chemical synthesis, cytotoxicity, uncultured microorganisms, genomic mining, Microbiology Spectrum

Monastrol has long occupied a special place in the cancer pharmacology literature. Originally identified as a small molecule that binds kinesin Eg5, a motor protein essential for proper spindle formation during cell division, it has served as a prototypical antimitotic agent in numerous studies of cancer cell biology. But the compound’s story did not end there. More recent work revealed that monastrol also interacts with fascin, an actin-bundling protein that has emerged as a key player in tumor aggressiveness and metastatic behavior. By engaging fascin, monastrol disrupts the dynamics of microtubules and the bundling of actin filaments, ultimately impairing the ability of cancer cells to migrate. This dual activity made monastrol an attractive starting point for medicinal chemistry: a molecule whose binding features could be reverse-engineered to find improved analogs targeting the metastatic machinery of tumors.

The research team, led by Alejandro Rodríguez-Martínez and Horacio Pérez-Sánchez of UCAM Universidad Católica de Murcia, together with collaborators at the University of Granada, Fundación MEDINA, and the Instituto Murciano de Investigación Biosanitaria, set out to exploit that insight systematically. Their strategy centered on a ligand-based pharmacophore model, a simplified three-dimensional representation of the spatial and chemical features that a molecule must display to bind fascin effectively. Such models capture the essential hydrogen-bond donors and acceptors, hydrophobic regions, and aromatic features of a known binder, in this case monastrol, and allow computational filters to be applied across vast chemical databases. Rather than testing compounds one by one at the bench, the researchers let the pharmacophore do the first round of triage on a high-throughput screening library containing 1.6 million commercially available, combinatorial compounds.

The virtual screening workflow was not a single calculation but a cascade of increasingly stringent filters. After the initial pharmacophore search identified molecules whose geometry and chemical functionality matched the monastrol-derived pattern, the top-ranking candidates were subjected to further physicochemical characterization, a step designed to weed out compounds with unfavorable drug-like properties before any laboratory resources were committed. The authors describe this as an optimized pipeline that integrates computational prediction with in vitro validation, a design philosophy that reflects the realities of modern drug discovery: computational methods can reduce the search space by orders of magnitude, but only experimental confirmation can establish that a predicted binder actually engages its target in solution and inside a living cell.

Two compounds emerged from this gauntlet with particularly compelling profiles. Z118298144 and Z17544625 both demonstrated strong binding to fascin in physicochemical assays, and both inhibited the actin-bundling activity that gives fascin its pro-metastatic function. The experimental validation relied in part on differential scanning fluorimetry, a technique that monitors the thermal stability of a protein in the presence and absence of a ligand; a genuine binder typically shifts the protein’s melting temperature, providing a quantitative and reproducible readout of binding. Complementary high-content imaging assays assessed fascin-dependent F-actin bundling directly, confirming that the binding events observed in the thermal shift experiments translated into functional inhibition of the protein’s biological activity.

The critical question, of course, was whether this molecular-level activity would matter inside an actual cancer cell. To answer it, the team turned to cellular experiments using colorectal cancer cell lines. Both compounds reduced the proliferation of CRC cells and impaired their migration at micromolar concentrations, a potency range that is respectable for early-stage chemical starting points and leaves room for optimization. Migration assays are particularly relevant in this context, because fascin’s role in tumor biology centers on the assembly of actin-based protrusions such as filopodia, which cancer cells use to invade surrounding tissue and metastasize. A compound that blocks fascin-mediated actin bundling is, in effect, targeting the physical apparatus of metastasis rather than simply killing dividing cells, and the researchers’ demonstration that both molecules hamper CRC cell migration suggests that this mechanism is genuinely engaged in the cellular context.

Structural detail on how the two hit compounds interact with fascin was obtained through molecular dynamics simulations, which followed the behavior of the fascin-ligand complexes over time after docking into the protein’s known binding regions. Fascin presents multiple binding pockets, including two actin-binding sites and a tubulin-interacting site, and the simulations tracked the minimum distances between each compound and key residues across these sites, along with hydrogen-bond networks that stabilize the bound poses. This atomistic layer of analysis supports the pharmacophore-based identification strategy and provides starting points for future structure-guided optimization, since the residues contacted by Z118298144 and Z17544625 can now be targeted deliberately in analog design.

Importantly, the researchers also addressed safety signals early in the characterization process. Supplementary dose-response experiments assessed the cytotoxicity of Z118298144 and monastrol in two non-cancerous human cell lines using a resazurin-based metabolic viability assay, providing an initial read on whether the new compound spares healthy cells at the concentrations that affect tumor cells. Such counterscreens are a standard but often underappreciated part of early drug discovery, and their inclusion in this study reflects a pipeline designed not merely to find binders but to find binders worth pursuing as therapeutic leads.

Beyond the two specific compounds, the study’s broader contribution is the validated workflow itself. The authors report that the protocol has been successfully adapted for application to additional cancer-related targets, expanding its potential utility across drug discovery programs. In an era when combinatorial chemistry has made billions of compounds synthetically accessible but experimental screening capacity remains finite, hybrid approaches that combine pharmacophore modeling, virtual screening, physicochemical filtering, and targeted in vitro validation offer a practical route through the haystack. The funding for the work came from a consortium of Spanish and European sources, including the Scientific Foundation of the Spanish Association against Cancer, the Andalusian Regional Government, the European Union Horizon 2020 REVERT project, and the Instituto de Salud Carlos III, with computational resources provided by the Plataforma Andaluza de Bioinformática, the Barcelona Supercomputing Center, and the NLHPC supercomputing infrastructure.

For patients with colorectal cancer, the road from a micromolar cell-culture hit to an approved medicine is long and uncertain, and neither Z118298144 nor Z17544625 is being presented as a ready therapy. What the study delivers instead is proof of concept: that a monastrol-derived pharmacophore can be used to mine a 1.6-million-compound library efficiently, that the resulting hits genuinely bind fascin and block its actin-bundling function, and that this molecular interference translates into reduced proliferation and impaired migration in colorectal cancer cells. Fascin has been implicated in the aggressiveness of multiple tumor types, and validated chemical inhibitors of the protein have been scarce. By pairing computational triage with rigorous biophysical and cellular validation, the Spanish team has added two new chemical starting points to a thin field and demonstrated a reusable pipeline that other laboratories can now apply to fascin and to further cancer targets. The next steps, medicinal chemists will note, involve improving potency, selectivity, and pharmacokinetic properties of the two hits, work that the published structural and biophysical data are well positioned to support.

Subject of Research: Identification of monastrol-derived fascin inhibitors as potential colorectal cancer therapeutics through virtual screening and experimental validation.

Article Title: Characterizing compounds targeting colorectal cancer derived from monastrol using high-through screening of an extensive combinatorial library

Article References: Characterizing compounds targeting colorectal cancer derived from monastrol using high-through screening of an extensive combinatorial library. (n.d.). https://doi.org/10.1186/s12935-026-04467-0

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04467-0

Keywords: colorectal cancer, monastrol, fascin, virtual screening, drug discovery, actin bundling, high-throughput screening, pharmacophore model, molecular dynamics, cellular assays, kinesin Eg5, anticancer compounds

The work addresses a persistent challenge in drug discovery: finding molecules that combine biological activity with practical, efficient and comparatively sustainable synthesis. Spiro compounds contain two ring systems joined through a single shared atom, creating a three-dimensional structure that can help molecules occupy biological binding sites in ways that flatter, more flexible compounds may not. Benzothiazoles, which contain fused benzene and thiazole rings, are also widely studied because their nitrogen and sulfur atoms can participate in interactions with proteins and other biomolecules. Combining these features creates a rigid, information-rich scaffold, but assembling such molecules can require multiple steps, long heating periods and substantial solvent use. The researchers therefore designed a multicomponent reaction that brings three starting materials together in a single vessel: 11H-indeno[1,2-b]quinoxalin-11-one, a substituted 2-aminobenzothiazole and isatoic anhydride. Potash alum was added as the catalyst, ethanol served as the solvent, and the mixture was irradiated at 600 watts in a microwave reactor while being stirred.

Optimization experiments showed why the final protocol performed better than the initial conditions. Without a catalyst, ethanol gave a 56% yield after 10 hours of conventional heating and a 59% yield after 40 minutes of microwave irradiation. Adding 20 mol% potash alum under conventional heating raised the yield to 67% and shortened the reaction time to six hours. Under microwave conditions, increasing the catalyst loading from 5 to 20 mol% progressively improved the yield, reaching 77% during the optimization sequence. At the selected catalyst loading, increasing microwave power from 400 to 600 watts improved conversion, while raising it further to 800 watts produced no meaningful gain. Extending irradiation from 10 to 20 minutes increased the model reaction yield from 80% to 95%. The researchers attributed the performance of ethanol partly to its polarity, microwave absorption and ability to solvate the reactants. Potash alum is proposed to activate the ketone and assist the sequence of bond-forming events that links the three components into the spirocyclic products. The resulting process uses a readily available catalyst and avoids the prolonged heating associated with the comparison method.

The chemical identity of the products was checked using several complementary analytical techniques rather than relying on yield alone. Fourier-transform infrared spectroscopy detected characteristic nitrogen–hydrogen, carbonyl, carbon–nitrogen and aromatic signals. Proton and carbon nuclear magnetic resonance spectroscopy provided evidence for the expected hydrogen and carbon environments, including resonances associated with the spiro carbon. Electrospray ionization mass spectrometry produced molecular-ion signals consistent with the proposed formulas. High-performance liquid chromatography was used to assess purity, which ranged from 92% to 99% across the reported compounds. The library incorporated a range of substituents on the benzothiazole ring, including nitro, methoxy, methyl, fluoro, bromo and chloro groups, as well as combinations of halogens. This systematic variation allowed the researchers to compare how changes in electronic character, size and lipophilicity affected the biological assays. The products were isolated as powders after cooling the reaction mixture, precipitation into ice-cold water and extraction with diethyl ether, followed by washing and drying.

The most striking biological result came from the MTT assay of cytotoxicity against MCF-7 breast cancer cells. The unsubstituted compound 3a provided a moderate baseline response, with an IC50 of 43.66 micromolar. Several substitutions performed poorly, including the methoxy derivative 3e and the methyl derivative 3f, both of which had IC50 values above 100 micromolar. A nitro group produced sharply different outcomes depending on its position: compound 3c showed an IC50 of 2.07 micromolar, whereas related compounds 3b and 3d were much weaker, with reported values of 92.15 and 24.66 micromolar, respectively. The standout was 3k, bearing both fluorine and bromine substituents, which reached 0.58 micromolar. For comparison, doxorubicin and cisplatin produced IC50 values of 1.03 and 4.61 micromolar, respectively, under the study’s conditions. The authors suggest that the paired electron-withdrawing halogens may improve activity partly by increasing lipophilicity. However, the test used a single cancer cell line and did not determine selectivity for cancer cells over healthy cells, mechanism of action or activity in animals. Those limitations mean that 3k should be viewed as a lead for investigation, not as a validated anticancer drug.

The antioxidant results revealed a contrasting structure–activity pattern. In the DPPH radical-scavenging assay, the unsubstituted compound 3a was the strongest performer, with a reported IC50 of 0.52 micromolar. The result suggests that preserving the parent aromatic and electronic arrangement favored the reaction with the stable radical used in the test. Most substitutions reduced activity substantially: compounds carrying nitro, methoxy, methyl or halogen groups generally had IC50 values above 100 micromolar. Compound 3d retained measurable activity at 35.47 micromolar, while the fluoro derivative 3g showed an IC50 of 83.45 micromolar. Ascorbic acid was included as the reference compound and had a reported IC50 of 17.56 micrograms per milliliter. Because the assay measures a chemical radical-scavenging reaction rather than antioxidant effects in a living organism, the result cannot by itself demonstrate therapeutic benefit. Still, the sharp difference between 3a and its substituted analogues gives the researchers a useful structure–activity clue: the modifications that enhanced the anticancer profile of 3k did not enhance its antioxidant performance.

The compounds also displayed activity against two Gram-positive bacteria in a Kirby–Bauer disk-diffusion assay. Compound 3d, containing a nitro group at the reported R4 position, produced the largest inhibition zone, measuring 18 millimeters against both S. aureus and B. subtilis. Compound 3e generated an 18-millimeter zone against B. subtilis, while 3f produced an 11.66-millimeter zone against the same organism. The dichloro derivative 3j showed a notable 11-millimeter zone against S. aureus, and several fluoro-, bromo- and chloro-substituted compounds showed moderate effects. The reference antibiotic ciprofloxacin produced inhibition zones of 21 to 24 millimeters in the reported comparisons. These results suggest that antibacterial activity depended on a different balance of electronic effects and lipophilicity from the one associated with cytotoxicity. In particular, a nitro group at one position was more favorable for bacterial inhibition than the same functional group at other positions. Since disk diffusion depends on both antimicrobial action and a compound’s ability to move through the assay medium, further tests would be needed to determine minimum inhibitory concentrations, activity against additional organisms and the underlying molecular targets.

Computational analysis provided a molecular explanation for why 3k, 3c and 3d emerged as leading candidates. The researchers docked the compounds into the breast cancer-associated protein structure identified by PDB code 3EQM using the Glide XP protocol. Compound 3k produced the most favorable reported docking score, −8.41957, together with a Glide energy of −53.911 kilocalories per mole. Compounds 3c and 3d also scored strongly, at −8.36215 and −8.21235, respectively, compared with −6.88115 for the protein’s co-crystallized ligand in the redocking comparison. The predicted interactions for 3k included a hydrogen bond involving a nitrogen atom in its quinoxalinone region, pi–pi stacking with tryptophan 224, hydrophobic contacts with valine, methionine and isoleucine residues, and a halogen bond involving bromine and arginine 375. A 100-nanosecond molecular-dynamics simulation suggested that the 3k–3EQM complex remained stable, with limited ligand fluctuation and persistent contacts, including a pi–pi interaction with tryptophan 224. QikProp calculations further indicated that the compounds met Lipinski’s rule of five, while 3k and 3j showed high predicted permeability and potential central nervous system exposure. These computational findings are useful for prioritizing experiments, but docking scores and in silico pharmacokinetics do not substitute for biochemical, cellular, toxicological or animal studies. The study’s central advance is therefore a practical synthesis and a set of testable leads whose activities can now be examined with more demanding models.

The study also illustrates why multifunctional screening can reveal trade-offs within one chemical series. The derivatives were not uniformly active across assays: structural changes that favored interaction with the breast cancer-associated protein did not necessarily improve radical scavenging or bacterial inhibition. This divergence is scientifically useful because it indicates that the scaffold can be tuned toward different biological objectives rather than treated as a single-purpose template. The reported antioxidant mechanism should nevertheless be interpreted cautiously. DPPH measures reaction with a stable laboratory radical and does not establish how a compound behaves in cells, where uptake, metabolism, redox cycling and toxicity can alter the outcome.

Further validation would need to connect the computational predictions with direct experiments. The proposed contacts between 3k and 3EQM could be tested through biochemical binding or inhibition studies, while broader cell panels could assess whether its effect is selective for MCF-7 cells. Additional antibacterial measurements, including minimum inhibitory concentrations, would distinguish growth inhibition from differences in diffusion through agar. The favorable ADME-Tox predictions are similarly prioritization tools rather than evidence of safe exposure in an organism. Even so, combining rapid synthesis, analytical confirmation, phenotypic assays and modeling gives the series a rational starting point for refining potency, selectivity and pharmacological behavior.

Subject of Research: Microwave-assisted synthesis and biological evaluation of spiro-benzothiazole derivatives

Article Title: Boosting microwave-assisted synthesis via potash alum for bioactive spiro-benzothiazoles with its computational profile

Article References: Gamit, A. S., Humal, T. R., Desai, P. S., Shaikh, F. M., Patel, N. B., Shah, A. B., Limbachiya, N. G., Prajapati, A., Patel, H. D., & Patel, V. M. (2026). Boosting microwave-assisted synthesis via potash alum for bioactive spiro-benzothiazoles with its computational profile. Discover Green Chemistry, 1(1), Article 25. https://doi.org/10.1007/s44509-026-00027-x

Image Credits: AI Generated

DOI: 10.1007/s44509-026-00027-x

Keywords: spiro-benzothiazoles, microwave chemistry, potash alum, green synthesis, anticancer compounds, antioxidant activity, antibacterial activity, molecular docking, Boosting, microwave-assisted, synthesis, potash